

Ferm PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2959-B		SERIAL NO. <u>10/648,136</u> --to be assigned-- Div of 09/921,667	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Kendall M. MOHLER et al.			
				FILING DATE August 26, 2003		GROUP <u>1644</u> --to be assigned--	
U.S. PATENT DOCUMENTS							
EXAMINER	A1	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
mtt	A1	5,304,635	04/19/94	Imam et al.	X	X	
mtt	A2	5,480,981	01/02/96	Goodwin et al.			
mtt	A3	5,677,430	10/14/97	Goodwin et al.			
mtt	A4	5,840,869	11/24/98	Mosley et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
mtt	B1	WO 03/043583A2	5/30/03	WIPO	X	X	
mtt	B2	EP 0460846A	12/11/91	EPO			
mtt	B3	WO 99/40187	08/12/99	WIPO			
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
mtt	C1	Bengtsson Å. et al., "Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation," <i>J. Leukoc. Biol.</i> 58:683-689 (1995).					
mtt	C2	Blom AB et al., "Immune complexes, but not streptococcal cell walls or zymosan, cause chronic arthritis in mouse strains susceptible for collagen type II auto-immune arthritis," <i>Cytokine</i> 1999; 11:1046-1056, XP-001089856.					
mtt	C3	Caligaris-Cappio F. et al., "Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity," <i>Clin. Exp. Rheumatol.</i> 13:339-343 (1995).					
mtt	C4	Durkop H. et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease," <i>Cell</i> 68:421-427 (1992).					
mtt	C5	Erickson S. L. et al., "Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice," <i>Nature</i> 372:560-563 (1994).					
mtt	C6	Gilfillan M. C. et al., "Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines," <i>J. Immunol.</i> 160:2180-2187 (1998).					
mtt	C7	Gruss H-J et al., "Biological roles of CD30 ligand in CD30+ malignant lymphomas and T cell-dependent immune responses," <i>Exp Hematol (Charlottesville)</i> , 1995, 23:851, XP008005895.					
mtt	C8	Hamann D. et al., "CD30 expression does not discriminate between human Th1- and Th2-type T cells," <i>J. Immunol.</i> 156:1387-1391 (1996).					
mtt	C9	Horie R. and Watanabe T., "CD30: expression and function in health and disease," <i>Semin. Immunol.</i> 10:457-470 (1998).					
	C10	Joe B. and Wilder R. L., "Animal models of rheumatoid arthritis," <i>Mol. Med. Today</i> 5:367-369 (1999).					
EXAMINER <i>Maher Haddad</i>				DATE CONSIDERED <i>11/16/05</i>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2959-B		SERIAL NO. 10/648,136 -- to be assigned-- (Div of 09/921,667)	
INFORMATION DISCLOSURE CITATION (Supplemental Sheet)				APPLICANT Kendall M. MOHLER et al.			
				FILING DATE August 26, 2003		GROUP 1644 To be assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>mt</i>	C11	Koon H. B. and Junghans R. P., "Anti-CD30 antibody-based therapy," <i>Curr. Opin. Oncol.</i> 12:588-593 (2000).					
<i>mt</i>	C12	Körner H. et al., "Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system," <i>Eur. J. Immunol.</i> 27:1973-1981 (1997).					
<i>mt</i>	C13	Körner H. et al., "Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting," <i>J. Exp. Med.</i> 186(9):1585-1590 (1997).					
<i>mt</i>	C14	Kurts C. et al., "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells," <i>Nature</i> 398:341-344 (1999).					
<i>mt</i>	C15	Liu A. Y. et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> 84:3439-3443 (1987).					
<i>mt</i>	C16	Marino M. W. et al., "Characterization of tumor necrosis factor-deficient mice," <i>Proc. Natl. Acad. Sci. USA</i> 94:8093-8098 (1997).					
<i>mt</i>	C17	Mendel I. et al., "A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2 ^b mice: fine specificity and T cell receptor V β expression of encephalitogenic T cells," <i>Eur. J. Immunol.</i> 25:1951-1959 (1995).					
<i>mt</i>	C18	Mori L. et al., "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice," <i>J. Immunol.</i> 157:3178-3182 (1996).					
<i>mt</i>	C19	Nakamura T. et al., "Reciprocal regulation of CD30 expression on CD4 ⁺ T cells by IL-4 and IFN- γ ," <i>J. Immunol.</i> 158:2090-2098 (1997).					
<i>mt</i>	C20	Peschon J. J. et al., "TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation," <i>J. Immunol.</i> 160:943-952 (1998).					
<i>mt</i>	C21	Pfeffer K. et al., "Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to <i>L. monocytogenes</i> infection," <i>Cell</i> 73:457-467 (1993).					
<i>mt</i>	C22	Riechmann L. et al., "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327 (1988).					
<i>mt</i>	C23	Romagnani S. et al., "CD30 and type 2 T helper (Th2) responses," <i>J. Leukoc. Biol.</i> 57:726-730 (1995).					
<i>mt</i>	C24	Romagnani S., "Biology of human T _H 1 and T _H 2 cells," <i>J. Clin. Immunol.</i> 15(3):121-129 (1995).					
<i>mt</i>	C25	Rothe J. et al., "Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by <i>Listeria monocytogenes</i> ," <i>Nature</i> 364:798-802 (1993).					
<i>mt</i>	C26	Smith C. A. et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," <i>Cell</i> 73:1349-1360 (1993).					
<i>mt</i>	C27	Sundarapandiyam K. et al., "Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells," <i>J. Immunol. Methods</i> 248:113-123 (2001).					
<i>mt</i>	C28	Wiley S. R. et al., "Reverse signaling via CD30 ligand," <i>J. Immunol.</i> 157:3635-3639 (1996).					
<i>mt</i>	C29	Winter G. and Harris W. J., "Antibody-based therapy," <i>TIPS</i> 14:139-143 (1993).					
<i>mt</i>	C30	Yamamoto J. et al., "CD30 expression on circulating memory CD4 ⁺ T cells as a Th2-dominated situation in patients with atopic dermatitis," <i>Allergy</i> 55:1011-1018 (2000).					
EXAMINER <i>Maher Heekel</i>				DATE CONSIDERED <i>11/16/05</i>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							